Van Agt S, Gobet F, Sibert L, Leroi A-M, Grise P
Service d'urologie, CHU Charles-Nicolle, 1, rue de Germont, 76031 Rouen cedex, France.
Prog Urol. 2011 Mar;21(3):218-25. doi: 10.1016/j.purol.2010.07.016.
We evaluate the efficacy of hyaluronate acid instillation for treatment of interstitial cystitis (IC).
From March 2008 to May 2009, a prospective study included 31 patients. We used the new definition of IC established by the ICS in 2002. Patients have a urinalysis, a cystoscopy, a hydrodistension test and bladder biopsies. The urodynamic evaluation was not systematic. Patients received weekly six instillations of 40mg (50ml) intravesical hyaluronate acid. We evaluated the efficacy and safety of treatment with two specific questionnaires of interstitial cystitis filled before and after 6 weeks of treatment: the O'Leary-Sant and Pelvic pain and Urgency/Frequency (PUF).
Four groups were defined: good response, partial response, poor response and no response. They were composed by 14 patients (45%), two (7%), seven (22%) and eight patients (26%). We obtained 52% positive response (good response and partial response) after 6 weeks of treatment. Patients with cystoscopy and histology abnormal had a response rate of 60%. No serious side effects were observed.
Hyaluronate acid has a place in the treatment of interstitial cystitis with an efficiency comparable to other treatments and good tolerance. The response rate to treatment can be improved by better selection of patients, particularly those having a cystoscopy and histology abnormal.
我们评估透明质酸膀胱灌注治疗间质性膀胱炎(IC)的疗效。
2008年3月至2009年5月,一项前瞻性研究纳入了31例患者。我们采用了国际尿控学会(ICS)2002年制定的IC新定义。患者接受了尿液分析、膀胱镜检查、膀胱水扩张试验及膀胱活检。尿动力学评估并非常规进行。患者每周接受6次40mg(50ml)膀胱内透明质酸灌注。我们使用两份间质性膀胱炎特异性问卷,分别在治疗6周前后填写,以评估治疗的疗效和安全性:O'Leary-Sant问卷以及盆腔疼痛与尿急/尿频(PUF)问卷。
分为四组:良好反应、部分反应、反应不佳和无反应。分别由14例患者(45%)、2例(7%)、7例(22%)和8例患者(26%)组成。治疗6周后,我们获得了52%的阳性反应(良好反应和部分反应)。膀胱镜检查和组织学异常的患者反应率为60%。未观察到严重副作用。
透明质酸在间质性膀胱炎的治疗中占有一席之地,其疗效与其他治疗方法相当,耐受性良好。通过更好地选择患者,尤其是膀胱镜检查和组织学异常的患者,可提高治疗反应率。